Is CJC-1295 Legal in the US? (2026 Research Status)
In a landmark 2006 study, a single subcutaneous injection of CJC-1295 increased growth hormone levels by up to 10-fold and sustained elevated IGF-1 concentrations for nearly a week in healthy adults Teichman et al., 2006. That kind of potency caught the attention of researchers — and regulators.
If you’ve been exploring the world of growth hormone-releasing peptides, you’ve probably encountered CJC-1295. It’s discussed in bodybuilding forums, longevity communities, and clinical research circles alike. But the question that matters most before anything else is straightforward: is CJC-1295 legal in the United States?
The answer is more layered than a simple yes or no. This guide walks through the compound’s regulatory history, its current legal classification, and what the landscape looks like heading into 2026.
What Is CJC-1295?
CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH). In plain terms, it’s a lab-engineered peptide designed to signal the pituitary gland to release more growth hormone (GH).
The original version — CJC-1295 with DAC (Drug Affinity Complex) — was developed by ConjuChem Biotechnologies, a Canadian pharmaceutical company. The DAC technology was designed to extend the peptide’s half-life dramatically by allowing it to bind to albumin, a protein in the blood. This is what made CJC-1295 different from earlier GHRH fragments: instead of lasting minutes, it could remain active for days.
There’s also a related compound often called CJC-1295 without DAC (sometimes referred to as Mod GRF 1-29). This is essentially a modified version of the first 29 amino acids of GHRH with a few substitutions to improve stability. It has a much shorter half-life than the DAC version and is sometimes grouped under the same name in online discussions, which creates confusion.
For a deeper dive into the compound’s pharmacology, see our full CJC-1295 compound profile.
How Does CJC-1295 Work?
CJC-1295 works by mimicking the body’s natural GHRH. It binds to GHRH receptors on somatotroph cells in the anterior pituitary gland, triggering the release of growth hormone in a pulsatile pattern.
Research suggests that this pulsatile release is important. Unlike exogenous growth hormone administration, which delivers a constant signal, CJC-1295 appears to preserve the body’s natural GH secretion rhythm. A 2008 study found that even during continuous stimulation with CJC-1295, pulsatile GH secretion persisted, which researchers noted may be relevant for maintaining physiological hormone patterns Ionescu et al., 2008.
The downstream effects include elevated IGF-1 (insulin-like growth factor 1) levels, which is the primary mediator of many of growth hormone’s anabolic and metabolic effects. Studies indicate that these elevated IGF-1 levels can persist for up to 11–14 days following a single injection of the DAC version.
The Research History: From Pharma Lab to Gray Market
CJC-1295’s journey is a case study in how a compound can outlive its pharmaceutical development.
Early 2000s: ConjuChem Biotechnologies began developing CJC-1295 with DAC as a potential treatment for growth hormone deficiency and other conditions. Phase I and Phase II clinical trials were conducted, with the Teichman et al. 2006 study representing some of the most cited early human data.
Mid-2000s: The company (later rebranded as Transition Therapeutics) continued clinical work, but the compound never progressed to Phase III trials. The reasons were multifactorial — they included questions about long-term safety, the complexity of the DAC technology, and shifting pharmaceutical priorities.
Late 2000s–2010s: Despite never receiving FDA approval, CJC-1295 began appearing in the research chemical market. Peptide suppliers sold it labeled “for research purposes only — not for human consumption.” This is a common legal workaround that exists in a regulatory gray area.
2010s: The compound gained significant popularity in fitness and anti-aging communities, often stacked with other peptides like Ipamorelin. This visibility eventually drew regulatory scrutiny.
FDA Regulatory Status: Where CJC-1295 Stands
Here’s the core regulatory reality: CJC-1295 has never been approved by the FDA for any medical use in humans. It is not an approved drug, and it cannot legally be marketed, prescribed, or sold as a treatment for any condition.
However, it’s also important to understand what CJC-1295 is not:
- It is not a controlled substance. The DEA does not classify CJC-1295 as a Schedule I–V drug. It is not subject to the same restrictions as anabolic steroids or certain other performance-enhancing substances.
- It is not banned outright for all purposes. Researchers can legally purchase and use CJC-1295 in legitimate laboratory settings.
The critical distinction lies in intent and marketing. Selling CJC-1295 for human consumption or therapeutic use is illegal. Selling it as a research chemical occupies a different — and contested — legal space.
The 2023 FDA Crackdown on Compounded Peptides
The regulatory landscape shifted significantly in 2023 when the FDA issued guidance identifying certain bulk drug substances as posing “significant safety risks” when used in compounding. CJC-1295 was placed on this list.
This action primarily targeted compounding pharmacies that were preparing CJC-1295 for patient use under physician supervision — a practice that had grown substantially in the peptide therapy space. The FDA’s position was that insufficient safety and efficacy data existed to support its use in compounded medications.
This guidance effectively removed CJC-1295 from the legitimate compounding pharmacy supply chain. For a broader overview of how peptide regulations have evolved, see our guide on peptide legality in 2026.
So, Is CJC-1295 Legal in 2026? The Nuanced Answer
As of 2026, the legal status of CJC-1295 in the US can be summarized as follows:
| Context | Legal Status |
|---|---|
| FDA-approved medication | ❌ Not approved for any use |
| Controlled substance (DEA) | ❌ Not scheduled |
| Research chemical (laboratory use) | ✅ Generally legal to purchase and possess |
| Compounded pharmaceutical | ❌ Excluded from compounding lists |
| Marketing for human consumption | ❌ Illegal |
| Personal possession | ✅ Not criminalized (not a controlled substance) |
The practical takeaway: CJC-1295 exists in a regulatory gray zone. It’s not illegal to own, but it is illegal to sell for human use, and it cannot be obtained through legitimate medical channels.
This creates a situation where the compound is widely available from research chemical suppliers, but the quality, purity, and actual contents of what’s being sold are entirely unregulated. A 2023 analysis of peptide vendors found significant discrepancies between labeled and actual peptide content in a substantial portion of products tested, which is a safety concern that extends beyond the legal question.
What This Means for Researchers
If you’re studying CJC-1295 in a legitimate research context, the compound remains accessible through chemical suppliers. However, researchers should be aware of several considerations:
Sourcing matters. Third-party testing (HPLC, mass spectrometry) is the standard for verifying peptide identity and purity. Certificate of Analysis documentation should accompany any research-grade purchase.
Regulatory monitoring is ongoing. The FDA’s position on research peptides could continue to evolve. Compounds that gain significant public attention tend to attract regulatory action.
The science is still developing. While early studies showed promising pharmacological profiles, CJC-1295 has not undergone the rigorous Phase III clinical trials that would be required for FDA approval. Long-term safety data in humans remains limited. A review of growth hormone secretagogues noted that while these compounds may support GH release, the clinical significance and safety profile of many of them require further investigation Sigalos & Pastuszak, 2018.
For those looking to source the compound for research purposes, we’ve compiled a vendor evaluation guide for CJC-1295 that covers quality indicators and red flags.
The Bottom Line
CJC-1295 is not a controlled substance, and simple possession is not a criminal offense in the US. However, it has never been FDA-approved, it has been excluded from pharmaceutical compounding, and it cannot legally be marketed for human use. Its availability as a “research chemical” persists in a gray area that the FDA has signaled it may continue to scrutinize.
The compound’s research history is genuinely interesting — the sustained GH release profile demonstrated in early clinical work was noteworthy. But interest in the science should be paired with a clear-eyed understanding of the regulatory and safety landscape.
Frequently Asked Questions
Can I legally buy CJC-1295 in the US?
You can purchase CJC-1295 from research chemical suppliers, as it is not a DEA-controlled substance. However, it is not FDA-approved for human use, and vendors are technically only permitted to sell it for laboratory research purposes. Buying it for personal therapeutic use falls outside the intended legal framework.
Is CJC-1295 banned by WADA?
Yes. CJC-1295 is prohibited by the World Anti-Doping Agency (WADA) under the category of “Growth Hormone Releasing Factors.” It is banned both in- and out-of-competition. Athletes subject to anti-doping testing should be aware that CJC-1295 can be detected in blood and urine samples.
Why was CJC-1295 removed from compounding pharmacies?
In 2023, the FDA identified CJC-1295 as a bulk drug substance that poses significant safety risks when used in compounding. The agency cited insufficient safety and efficacy data as the basis for this determination. This removed it from the list of substances that compounding pharmacies can legally prepare for patients.
What’s the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC includes a Drug Affinity Complex that extends its half-life to approximately 6–8 days by binding to albumin in the bloodstream. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of roughly 30 minutes. The two compounds are pharmacologically distinct despite often being discussed interchangeably online.
Could CJC-1295 become FDA-approved in the future?
It’s theoretically possible but unlikely in the near term. FDA approval would require a pharmaceutical company to invest in full Phase I–III clinical trials, which is a costly and lengthy process. Given that the original developer discontinued clinical development, there is currently no active pathway toward approval. The regulatory environment for peptides has also become more restrictive, not less, in recent years.
